Bracco's Bead-Free Bubbles: A New Bid to Scale Cell Therapy Production

PRINCETON, NJ – September 09, 2026 – In the high-stakes world of cell therapy, the promise of cures for cancer and other devastating diseases often collides with the harsh reality of manufacturing. The complex, costly, and time-consuming process of producing treatments like CAR-T has created a significant bottleneck, limiting patient access. Now, a diagnostic imaging giant is stepping into the therapeutic arena with a novel solution that aims to pop that very bubble.

Bracco Imaging, a global firm historically known for its contrast agents, has launched the BubbleGen™ CD3+ T Cell Selection Kit. Built on the company’s deep expertise in microbubble technology, the kit offers a bead-free method for isolating the T-cells that form the backbone of many advanced therapies. By replacing the industry-standard magnetic beads with dissolvable microbubbles, Bracco is making a bold claim: it can make cell therapy manufacturing simpler, cheaper, and more scalable.

A Gentler, Cleaner Approach to Cell Selection

Cell selection is the critical first step in manufacturing therapies like CAR-T, where a patient's T-cells are harvested, genetically engineered to fight cancer, and reinfused. For decades, the go-to method for this delicate sorting process has been magnetic-activated cell sorting (MACS). This technique involves tagging target cells with tiny magnetic particles (beads) and using powerful magnets to separate them from the rest of the sample.

While effective, this magnetic approach has well-known drawbacks. The process can be harsh on cells, inducing stress that may compromise their therapeutic potency. Furthermore, the risk of residual magnetic particles remaining in the final product is a persistent concern for regulators and clinicians, necessitating complex and time-consuming wash steps. "The industry standard magnetic bead-based approach adds complexity, time, and cost to workflows – the enemies of scale," the company stated in its announcement.

Bracco’s BubbleGen technology offers a fundamentally different approach. Instead of magnetic particles, it uses lipid microbubbles coated with antibodies that specifically target CD3+ T-cells. When mixed with a blood sample, these bubbles bind to the desired cells. Through a gentle process, the cell-bubble complexes are separated, after which the microbubbles naturally dissipate, leaving behind a pure population of T-cells, free from any foreign particles.

“Cell therapy manufacturing requires technologies that can scale with the growing demands of the industry while reducing complexity and cost,” said Sophie He, VP of Cell Therapy at Bracco Imaging. “By providing a ready-to-use CD3+ selection kit, we are helping researchers accelerate process development today while building a foundation for the next generation of cell therapies.”

The key advantage, according to the company, is minimizing cell perturbation. This gentle handling is critical for preserving the health and functionality of the cells, which can directly impact the effectiveness of the final therapy. “BubbleGen provides researchers with a bead-free approach that combines workflow simplicity with the flexibility needed to support emerging cell therapy applications,” added Thierry Bettinger, R&D Director at Bracco’s Research Center in Geneva.

Unlocking Scale and Driving Down Cost

The ultimate goal for any new manufacturing tool in this space is to tackle the prohibitive cost of cell therapies, which can run into hundreds of thousands of dollars per patient. Experts widely agree that a significant portion of this cost is tied to the complex, manual, and lengthy manufacturing process, often referred to as the cost of goods (COGS).

Bracco's bead-free system targets this challenge directly. By eliminating the cost of magnetic beads and simplifying downstream processing steps required to remove them, the technology has the potential to reduce material and labor expenses. According to one industry analyst, non-magnetic methods are "highly sought after to overcome manufacturing bottlenecks" because they can lead to higher cell viability and functionality, which is critical for sensitive cell therapies. This translates into fewer batch failures and a more efficient, cost-effective process overall.

The promise of scalability is equally compelling. For cell therapies to become mainstream treatments rather than niche options for the few, production must move from a bespoke, lab-scale process to an industrialized, automated one. Technologies that are easily integrated into closed, automated systems are essential for this transition. While magnetic systems can be automated, the presence of beads adds a layer of complexity. A bead-free workflow, in theory, is more amenable to streamlined automation, enabling higher throughput to meet growing patient demand.

The launch of the CD3+ kit, designed for T-cell isolation in CAR-T and TCR-T development, is just the beginning. The company has signaled this is the first of multiple planned expansions, suggesting a future portfolio targeting other critical cell types used in regenerative medicine and immunology.

A Strategic Pivot for a Diagnostic Giant

The move into the cell therapy toolkit market represents a significant strategic diversification for the Bracco Group. Founded in 1927, the Italian multinational has built its reputation and a €2 billion annual revenue stream primarily on diagnostic imaging products. Its expertise in microbubbles, for instance, comes from decades of developing them as contrast agents for ultrasound.

This pivot is a calculated decision to leverage that core competency in a new, high-growth sector. The cell and gene therapy market is expanding rapidly, but its progress is tethered to the evolution of its manufacturing tools. By positioning itself as an enabler of this next-generation medicine, Bracco is tapping into a burgeoning market while aligning with its broader corporate mission of advancing precision medicine.

This is not a casual foray. The company invests roughly 9% of its turnover in R&D and has clearly allocated significant resources to the BubbleGen platform. By moving from diagnostics—identifying the problem—to providing tools for therapeutics—enabling the solution—Bracco is expanding its role across the patient care continuum. This strategic expansion diversifies its portfolio beyond a mature market and positions it as a key innovator in one of modern medicine’s most exciting fields.

The Path to Clinical Adoption

Despite its promise, BubbleGen faces a challenging road ahead. The CD3+ kit is currently available for "Research Use Only" (RUO), a standard first step for new tools. For it to be used in producing therapies for patients, Bracco must develop a clinical-grade version that complies with Good Manufacturing Practices (GMP), the stringent quality standards required by regulators like the FDA and EMA.

This transition is a significant hurdle, requiring extensive validation and documentation. Furthermore, the cell therapy industry is notoriously conservative when it comes to manufacturing processes. Companies and contract manufacturers invest heavily in validating their workflows and are often reluctant to switch from established, approved methods without overwhelming proof of a new technology's superiority, safety, and reliability.

Bracco will need to generate robust data demonstrating that BubbleGen not only matches but exceeds the performance of entrenched magnetic systems in terms of cell purity, recovery, and viability. It must also overcome the inertia and retooling costs associated with adopting a new platform. However, the company is actively engaging the scientific community, showcasing the technology this week at the CAR-TCR Summit in Boston to gather feedback and build momentum.

While the claims of a simpler, cheaper, and gentler process are compelling, the ultimate success of BubbleGen will depend on its performance in the real world of clinical manufacturing, where consistency and quality are paramount. If Bracco can deliver on its promises, its tiny bubbles could make a very big splash in the future of medicine.